DE3872563D1 - Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme. - Google Patents

Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme.

Info

Publication number
DE3872563D1
DE3872563D1 DE8888303144T DE3872563T DE3872563D1 DE 3872563 D1 DE3872563 D1 DE 3872563D1 DE 8888303144 T DE8888303144 T DE 8888303144T DE 3872563 T DE3872563 T DE 3872563T DE 3872563 D1 DE3872563 D1 DE 3872563D1
Authority
DE
Germany
Prior art keywords
liposomes
cells
nucleosides
phosphorylated
viral dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8888303144T
Other languages
English (en)
Other versions
DE3872563T2 (de
Inventor
John N Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE3872563D1 publication Critical patent/DE3872563D1/de
Publication of DE3872563T2 publication Critical patent/DE3872563T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE8888303144T 1987-04-10 1988-04-08 Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme. Expired - Lifetime DE3872563T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3717887A 1987-04-10 1987-04-10
US17778888A 1988-04-05 1988-04-05

Publications (2)

Publication Number Publication Date
DE3872563D1 true DE3872563D1 (de) 1992-08-13
DE3872563T2 DE3872563T2 (de) 1992-12-03

Family

ID=26713879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8888303144T Expired - Lifetime DE3872563T2 (de) 1987-04-10 1988-04-08 Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme.

Country Status (8)

Country Link
EP (1) EP0286418B1 (de)
JP (1) JPH02501576A (de)
AT (1) ATE77945T1 (de)
AU (1) AU601848B2 (de)
CA (1) CA1315684C (de)
DE (1) DE3872563T2 (de)
IL (1) IL86009A (de)
WO (1) WO1988007854A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
JPH03501253A (ja) * 1987-09-22 1991-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5817638A (en) * 1988-07-07 1998-10-06 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
IE882585L (en) * 1988-08-25 1990-02-25 Prendergast Patrick T Viral treatment system
US5051361A (en) * 1988-10-19 1991-09-24 Sigma Chemical Company AZT immunoassays, derivatives, conjugates and antibodies
FR2640508B1 (fr) * 1988-12-19 1994-07-01 Dietlin Francois Nouvelles compositions et nouveaux produits pharmaceutiques assurant la regeneration de leucocytes et leur emploi pour le traitement du syndrome immuno-deficitaire
CA2055497A1 (en) * 1989-03-13 1990-09-14 Kenneth N. Matsumura Method for reducing side effects of a drug
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
AU7920491A (en) * 1990-06-21 1992-01-02 Patrick T. Prendergast Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
US5137876A (en) * 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE69531499T2 (de) * 1994-10-03 2004-06-24 Infectio Recherche Inc., Sainte-Foy Liposomenzubereitungen zur behandlung von viruserkrankungen
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
CA2270600A1 (en) * 1999-05-03 2000-11-03 Infectio Recherche Inc. Method and formulations for the treatment of diseases, particularly those caused by human immunodeficiency virus and leishmania
AU2003268087A1 (en) * 2002-08-23 2004-03-11 Ian Ma Liposomal gemcitabine compositions for better drug delivery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4604382A (en) * 1983-01-17 1986-08-05 Research Corporation 3'-amino-2',3'-dideoxycytidine and the pharmacologically acceptable salts thereof
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4622392A (en) * 1984-06-21 1986-11-11 Health Research Inc. (Roswell Park Division) Thiophospholipid conjugates of antitumor agents
IE56503B1 (en) * 1985-03-16 1991-08-14 Wellcome Found Antiviral nucleosides
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
WO1987001283A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxycytidine
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases

Also Published As

Publication number Publication date
DE3872563T2 (de) 1992-12-03
CA1315684C (en) 1993-04-06
IL86009A (en) 1991-09-16
AU1701788A (en) 1988-11-04
IL86009A0 (en) 1988-09-30
WO1988007854A1 (en) 1988-10-20
AU601848B2 (en) 1990-09-20
EP0286418B1 (de) 1992-07-08
EP0286418A1 (de) 1988-10-12
ATE77945T1 (de) 1992-07-15
JPH02501576A (ja) 1990-05-31

Similar Documents

Publication Publication Date Title
DE3872563D1 (de) Anti-retrovirale stoffe und dazugehoerige verabreichungssysteme.
ES2139810T3 (es) Retrovirus recombinantes.
ES2149267T3 (es) Carbonilos ciclicos substituidos y derivados de los mismos utiles como inhibidores de la proteasa retroviral.
DE69632256D1 (de) Antivirale proteine, dafür kodierende dna, und deren verwendung
ATE87319T1 (de) Inklusionskomplexe von 7-isopropoxy-isoflavon mit cyclodextrinen, verfahren zu deren herstellung und diese inklusionskomplexe enthaltende pharmazeutische praeparate.
EA199901031A1 (ru) Производные бензимидазола
PT88930A (pt) Processo para a preparacao de novos analogos de nucleosidos e de composicoes farmaceuticas que os contem
OA09124A (fr) Utilisation d'antagonistes de la morphine dans la préparation de médicaments à effet immunomodulateur et anti-viral, destinés notamment à traiter les états immuno-déficitaires acquis.
NL960024I1 (nl) Farmaceutisch preparaat omvattend 3'-deoxythymidine-2'-een (3'-deoxy-2',3'-didehydrothymidine) voor de behandeling van met retrovirus gesmette patiënten.
ES2081491T3 (es) Nuevo polipeptido y farmaco anti-vih preparado a partir de este polipeptido.
TR200102024T2 (tr) Yeni tedavi.
ES2105923A1 (es) Composiciones para el tratamiento de una infeccion y una enfermedad causadas por el virus de la hepatitis b (hbv).
ATE58478T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
Worthington et al. Late therapy of an arbovirus encephalitis in mice with interferon and interferon stimulators
RU93058325A (ru) Применение производных 1,3-оксатиолана для получения лекарственных препаратов для лечения или профилактики вирусной инфекции гепатита в, применение производных 1,3 - оксатиолана для лечения инфекций гепатита в, способ лечения гепатита в
DE68929084D1 (de) Arzneimittel zur Verhinderung einer Infektion mit dem für AIDS verantwortlichen Virus
ATE64855T1 (de) Zubereitungen und verfahren zum schutz von tlymphozyten gegen das krankheitsagens von lymphadenopathie und vom erworbenen immundepressionsyndrom.
TH3782EX (th) นิวคลีโอไซด์ที่ต่อต้านไวรัส
GT199000061A (es) Derivados amino acidos
TH13799EX (th) สารต้าน-เอชบีวี พิริมิดีนนิวคลีโอไซด์
TH3782A (th) นิวคลีโอไซด์ที่ต่อต้านไวรัส
DE69010736D1 (de) Anti-HIV Zusammensetzungen.
FR2690159B1 (fr) Derives d'acide 3,4-dihydro-2h-1,2,4-benzothiadiazine 1,1-dioxyde-3-carboxylique, leur preparation et les medicaments les contenant.
TH13510EX (th) ระบบนำส่งยาเฉพาะที่ที่ดีขึ้นซึ่งแทรกซึมผ่านผิวหนังได้เพิ่มขึ้น
MY101495A (en) Treatment of diseases caused by viruses

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee